[1] LARON Z. Insulin-like growth factor 1 (IGF-1):a growth Hormone, 2001
[2] ACCILI D, NAKAE J, KIM J J. Targeted gene mutationsdefine the roles of insulin and IGF-I receptors in mouse embryonic development, 1999
[3] VELDHUIS J D, LIEM A Y, SOUTH S. Differential impact of age,sex steroid hormones,and obesity on basalversus pulsatile growth hormone secretion in men as assessed inan ultrasensitive chemiluminescence assay, 1995
[4] METZGER DL, KERRIGAN J R, ROGOL A D. Gonadal steroid hormone regulation of the somtotrophic axis during puberty in humans. 1994. doi:10.1016/1043-2760(94)P3204-K
[5] DiMARTINO-NARDI J, WU R, VARNER R. The effect of luteinizing hormone-releasing hormone analog for central precociouspuberty on growth hormone (GH) and GH-binding protein, 1994
[6] HARRIS DA, van VLIET G, EGLI C A. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment witha potent luteinizing hormone-releasing hormone agonist, 1985
[7] SKLAR CA, ROTHENBERG S, BLUMBERG D. Suppression of the pituitary-gonadal axis in children with central precocious puberty:effects on growth,growth hormone,insulin-like growth factor-I,and prolactin secretion. 1991. doi:10.1210/jcem-73-4-734
[8] GALLUZZI F, SALTI R, BINDI G. Adult height comparison between boys and girls with precocious puberty after longterm gonadotropin-releasing hormone analogue therapy. 1998. doi:10.1080/08035259850158227
[9] SAGGESE G, PASQUINO A M, BERTELLONI S. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. 1995. doi:10.1111/j.1651-2227.1995.tb13632.x
[10] TATO′L, SAGGESE G, CAVALLO L. Use of combined Gn-RH agonist and hGH therapy for better attaining the goals in precocious puberty treatment. 1995. doi:10.1159/000184674
[11] PASQUINO A M, PUCARELLI I, SEGNI M. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. 1999
[12] MANSFIELD M J, RUDLIN C R, CRIGLER J F. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty, 1988
[13] KREITER M, BURSTEIN S, ROSENFIELD R L. Preserving adult height potential in girls with idiopathic true precocious puberty. 1990. doi:10.1016/S0022-3476(5)81074-1
[14] JUUL A, SCHEIKE T, NIELSEN C T. Serum insulin-like growth factor Ⅰ (IGF-Ⅰ) and IGF-binding protein 3 levels are increased in central precocious puberty:effects of two different treatment regimens with gonadotropin-releasing hormone agonists,without or in combination with an antiandrogen (cyproterone acetate), 1995
[15] JUUL A. Serum concentrations of free and total insulin-like growth factor-Ⅰ,IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty, 1996
[16] BELGOROSKY A, RIVAROLA M A. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies:implications for the onset of puberty. 1998(5). doi:10.1159/000023176
[17] MARIANGELA C, MARILENA D, SILVANA L. The acid-labile subunit of human ternary insulin-like growth actor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy, 2002
[18] 李嫔, 蔡德培. 补肾中药对青春期大鼠下丘脑生长抑素基因表达与蛋白表达的影响. 上海中医药杂志2003(5). doi:10.3969/j.issn.1007-1334.2003.05.022
[19] 俞建, 吴家敏, 杨毅. 滋阴泻火中药对大鼠中枢生长相关基因的影响. 中国医药学报2004(1). doi:10.3969/j.issn.1673-1727.2004.01.004 |
